Cardiovascular Safety of 0ral HypoglycemicTherapies

Cardiovascular Safety of 0ral HypoglycemicTherapies

F. Hosseinpanah

Obesity Research Center

Research Institute for Endocrine sciences

Shahid Beheshti University

of Medical Sciences

May19, 2011

Tehran

Agenda

• Some methodological issues on drug approval process
• Metformin
• Insulin secretoguges
• TZDs
• Acarbose,GLP1 analouges,DPP4 inhibitors
• Conclusion

Diabetes and CVD

• The  importance  of  abnormally  elevated  blood  glucose as a cardiovascular (CV) risk factor is well established epidemiologically
•  Glycated  hemoglobin  (HbA1c),  a marker of long-term glycemic control, is directly associated with CV risk and all-cause mortality